Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387.

Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the second Cytopia developed drug candidate in clinical studies and the first trialled in the United States, with the anticancer

vascular disrupting agent CYT997 now in Phase II clinical studies in Australia.

Over-activity of the JAK2 enzyme is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. This data suggests that the compound may exert a profound effect on the human disease.

Myelofibrosis results in a compromised ability of patients to produce sufficient blood cells and a reliance on organs other than the bone marrow, including the liver and spleen, to produce cells. Typical symptoms include an enlarged spleen and progressive anemia and poor overall survival.

"The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team," said Mr Andrew Macdonald, CEO of Cytopia. "Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target."

The clinical utility of CYT387 is also expected to have broader applicability in diseases driven by disregulated JAK2 signalling, including some cancers and various inflammatory conditions. Cytopia is

exploring the utility of CYT387 in these conditions.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the development of new drugs to treat cancer and other diseases. Cytopia conducts its drug development through subsidiaries based in Australia

and USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, currently being trialed in Phase II clinical studies. This compound is delivered orally as well as intravenously. Cytopia also has built on its range of JAK and other kinase inhibitors with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009.


'/>"/>
SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Registered nurses, licensed practical ... seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, February 25 ... Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who will discuss ...
(Date:2/11/2016)... ... 2016 , ... Florida Hospital presents Heart Health Awareness night on Sunday February ... the Amalie Arena. The puck drops at 6:00pm, but fans will have the opportunity ... to the game. The MEGA Heart will be located on Ford Thunder Alley and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA veteran franchise owner ... it’s the buildings of Nashville that will benefit. , “I’ve enjoyed being a part ... Nashville, there was no question that I would bring my business with me,” Bogacki ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... the healthcare industry, ranked among the top five firms in the “2015/2016 Best ... HIT Implementation Support and Staffing. KLAS is a research and insights firm on ...
(Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Community pharmacists can help improve ... the pharmacy through a custom-built medication synchronization program, Cardinal ... and owner at Schieber Family Pharmacy in ... a lot of patients enrolled in this medication synchronization ... a win for the patient, and it,s a win ...
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) announced ... February 25 at 11:30 a.m. Eastern Time to discuss its ... www.ionispharma.com . A webcast replay will be ... --> www.ionispharma.com . A webcast replay will be available ... Interested parties may listen to the call by dialing ...
Breaking Medicine Technology: